UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Transdermal drug delivery by in-skin electroporation using a microneedle array

International journal of pharmaceutics, 2010-09, Vol.397 (1), p.77-83

2010

Volltextzugriff (PDF)

Correlation between health literacy and health‐related quality of life in patients with diabetic peripheral neuropathy: The mediating role of self‐management

Nursing open, 2023-05, Vol.10 (5), p.3164-3177

2023

Volltextzugriff (PDF)

Optimized Preparation of in Situ Forming Microparticles for the Parenteral Delivery of Vinpocetine

Chemical and Pharmaceutical Bulletin, 2008/06/01, Vol.56(6), pp.796-801

2008

Volltextzugriff (PDF)

Experimental and modelling research of the accelerated calcium leaching of cement paste in ammonium nitrate solution

Construction & building materials, 2013-03, Vol.40, p.832-846

2013

Volltextzugriff (PDF)

EMT‐cancer cells‐derived exosomal miR‐27b‐3p promotes circulating tumour cells‐mediated metastasis by modulating vascular permeability in colorectal cancer

Clinical and translational medicine, 2021-12, Vol.11 (12), p.e595-n/a

2021

Volltextzugriff (PDF)

Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study

Nature communications, 2024-08, Vol.15 (1), p.7255-13

2024

Volltextzugriff (PDF)

Hydrologic characteristics and nitrogen removal performance by different formulated soil medium of bioretention system

Journal of cleaner production, 2021-03, Vol.290, p.125873, Article 125873

2021

Volltextzugriff (PDF)

Defining the biological functions and clinical significance of AKR1C3 in gastric carcinogenesis through multiomics functional analysis and immune infiltration analysis

Journal of Cancer, 2024-01, Vol.15 (9), p.2646-2658

2024

Volltextzugriff (PDF)

Exosome-transmitted miR-29a induces colorectal cancer metastasis by destroying the vascular endothelial barrier

Carcinogenesis (New York), 2023-06, Vol.44 (4), p.356-367

2023

Volltextzugriff (PDF)

miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-κb signaling pathway in mantle cell lymphoma

Experimental hematology, 2021-11, Vol.103, p.52-59.e2

2021

Volltextzugriff (PDF)

The architecture of silk-secreting organs during the final larval stage of silkworms revealed by single-nucleus and spatial transcriptomics

Cell reports (Cambridge), 2024-07, Vol.43 (7), p.114460, Article 114460

2024

Volltextzugriff (PDF)

Timdarpacept (IMM01) in combination with tislelizumab in prior anti-PD-1 failed classical Hodgkin lymphoma: An open label, multicenter, phase II study (IMM01-04) evaluating safety as well as preliminary anti-tumor activity

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.7017-7017

2024

Volltextzugriff (PDF)

A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Clinical cancer research, 2021-10, Vol.27 (20), p.5492-5501

2021

Volltextzugriff (PDF)

XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma：Updates of the Phase Ib Touch Study

Blood, 2022-11, Vol.140 (Supplement 1), p.6554-6555

2022

Volltextzugriff (PDF)

The anti-CD20 antibody-drug conjugates TRS005 in relapse/refractory CD20-positive B-cell non-Hodgkin lymphoma: A multicenter, open-label, single-arm, phase I study

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.3026-3026

2024

Volltextzugriff (PDF)

Application of tomography for solid calcium distributions in calcium leaching cement paste

Construction & building materials, 2012-11, Vol.36, p.913-917

2012

Volltextzugriff (PDF)

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Blood, 2023-11, Vol.142 (Supplement 1), p.1719-1719

2023

Volltextzugriff (PDF)

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population

Blood, 2023-11, Vol.142 (Supplement 1), p.6928-6928

2023

Volltextzugriff (PDF)

The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Lenalidomide in Chinese Patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma: Results of a Multicenter, Single-Arm, Phase 1b/2 Trial

Blood, 2021-11, Vol.138 (Supplement 1), p.1351-1351

2021

Volltextzugriff (PDF)

XPO1 Inhibitor (ATG-010) Plus Chemotherapy per Investigator's Choice for Heavily Pretreated Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Extranodal NK/T-Cell Lymphoma (ENKTL)：Preliminary Results from a Multicenter, Single-Arm, Phase Ib Study (TOUCH Trial)

Blood, 2021-11, Vol.138 (Supplement 1), p.2452-2452

2021

Volltextzugriff (PDF)

One-Pot Fabrication of K-Doped g-C3N4/SiO2Composite with Enhanced Photocatalytic Activity for Degradation of Tetracycline

Journal of the Chemical Society of Pakistan, 2021-04, Vol.43 (2), p.124-124

2021

Volltextzugriff (PDF)

One-Pot Fabrication of K-Doped g-C3N4/SiO2Composite with Enhanced Photocatalytic Activity for Degradation of Tetracycline

Journal of the Chemical Society of Pakistan, 2021, Vol.43 (2), p.124-124

2021

Volltextzugriff (PDF)

Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study

American journal of hematology, 2023-04, Vol.98 (4), p.571-579

2023

Volltextzugriff (PDF)

P1136: FIRST INTERIM ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e1828304-n/a

2023

Volltextzugriff (PDF)

PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN‐LABEL, MULTICENTER PHASE 1/2 TRIAL

HemaSphere, 2023-08, Vol.7 (S3), p.e21928ec-n/a

2023

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(42)

Sprache

Englisch
(42)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Transdermal drug delivery by in-skin electroporation using a microneedle array

Correlation between health literacy and health‐related quality of life in patients with diabetic peripheral neuropathy: The mediating role of self‐management

Optimized Preparation of in Situ Forming Microparticles for the Parenteral Delivery of Vinpocetine

Experimental and modelling research of the accelerated calcium leaching of cement paste in ammonium nitrate solution

EMT‐cancer cells‐derived exosomal miR‐27b‐3p promotes circulating tumour cells‐mediated metastasis by modulating vascular permeability in colorectal cancer

Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study

Hydrologic characteristics and nitrogen removal performance by different formulated soil medium of bioretention system

Defining the biological functions and clinical significance of AKR1C3 in gastric carcinogenesis through multiomics functional analysis and immune infiltration analysis

Exosome-transmitted miR-29a induces colorectal cancer metastasis by destroying the vascular endothelial barrier

miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-κb signaling pathway in mantle cell lymphoma

The architecture of silk-secreting organs during the final larval stage of silkworms revealed by single-nucleus and spatial transcriptomics

Timdarpacept (IMM01) in combination with tislelizumab in prior anti-PD-1 failed classical Hodgkin lymphoma: An open label, multicenter, phase II study (IMM01-04) evaluating safety as well as preliminary anti-tumor activity

A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma：Updates of the Phase Ib Touch Study

The anti-CD20 antibody-drug conjugates TRS005 in relapse/refractory CD20-positive B-cell non-Hodgkin lymphoma: A multicenter, open-label, single-arm, phase I study

Application of tomography for solid calcium distributions in calcium leaching cement paste

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population

The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Lenalidomide in Chinese Patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma: Results of a Multicenter, Single-Arm, Phase 1b/2 Trial

XPO1 Inhibitor (ATG-010) Plus Chemotherapy per Investigator's Choice for Heavily Pretreated Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Extranodal NK/T-Cell Lymphoma (ENKTL)：Preliminary Results from a Multicenter, Single-Arm, Phase Ib Study (TOUCH Trial)

One-Pot Fabrication of K-Doped g-C3N4/SiO2Composite with Enhanced Photocatalytic Activity for Degradation of Tetracycline

One-Pot Fabrication of K-Doped g-C3N4/SiO2Composite with Enhanced Photocatalytic Activity for Degradation of Tetracycline

Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study

P1136: FIRST INTERIM ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN‐LABEL, MULTICENTER PHASE 1/2 TRIAL

Suchergebnisse filtern